Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Singapore leads medical tourism within APAC with Novartis’ Kymriah approval, says GlobalData

The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are gaining traction. With the approval of Novartis’ Kymriah, Singapore is now all set to deliver the transformative treatment for cancers and takes the lead in medical tourism within Asia-Pacific (APAC), […]
Read more

COVID-19 survivors may face long-term complications, says GlobalData

Given recent findings that nearly one-third of previously hospitalized COVID-19 patients in the UK are readmitted for further treatment within five months after infection, and one in eight COVID-19 patients died in that same timeframe, further follow-up on the long-term effects of the disease needs to be conducted, along with treatments to prevent these outcomes, […]
Read more

Asthma low patient adherence shows need for personalized and convenient medications, says GlobalData

Primary research by data and analytics company GlobalData has revealed that 80% of asthma patients do not take their medication effectively. The reasons for this poor patient adherence are numerous and can include poor inhaler technique, poor perception, complex regimens and the cost of medication. Tiffany Chan, Immunology Analyst at GlobalData, discusses what medicines are […]
Read more

World Parkinson’s Day 2021: Urgent need for disease-modifying drugs to halt disease progression, says GlobalData

There are diverse development strategies and trends in the Parkinson’s disease (PD) treatment at present, however only a few of them address the pressing need for a disease-modifying therapy (DMT). This reflects the various complexities in the process of understanding the exact pathophysiology of the disease through bringing new therapies into this market. Therefore, if […]
Read more

AstraZeneca needs to regain public trust by showing benefits of COVID-19 vaccine far outweigh risks, says GlobalData

Following the news that the European Medicines Agency (EMA) has confirmed a possible link between very rare cases of unusual blood clots after vaccination with AstraZeneca’s COVID-19 vaccine Vaxzevria; Philipp Rosenbaum, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “AstraZeneca has had its fair share of bad luck […]
Read more

Immuno-Oncology the most transformative treatment since chemotherapy is set to benefit more patients

Immuno-oncology (IO) agents, particularly immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have extended the survival of patients in many cancer types and current investigational approaches in the industry and academia will lead to even further clinical improvement, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Immuno-Oncology – Market Analysis, Trends, […]
Read more

Newron’s Xadago set to reach $246m by 2029 with new label extension potential in PD-LID, says GlobalData

Newron Pharmaceuticals and Zambon’s planned pivotal trial to evaluate a label extension for Xadago (safinamide) in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID) is a strategic approach to boost Xadago’s peak sales and strengthen its competitive advantage in the PD space. This strategy usually helps companies to expand their existing patient pool and capitalize on […]
Read more

COVID-19 is disproportionately affecting women with major depressive disorder, says GlobalData

The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences for the mental health of women with major depressive disorder (MDD), which is expected to increase in prevalence after the pandemic, says GlobalData, a leading data and analytics company. Ana Fernandez Menjivar, MSc DLSHTM, Senior Epidemiologist at GlobalData, comments: “The higher prevalence of MDD […]
Read more

Non-alcoholic fatty liver disease inclusion into national prevention program likely to reduce NASH prevalence in India, says GlobalData

Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of a wide spectrum of liver diseases including non-alcoholic steatohepatitis (NASH) in India. A proactive focus on NAFLD if translated into action can halt its prognosis to NASH, thereby reducing its prevalence in the country, says GlobalData, a leading data and analytics company. In […]
Read more

Although Novartis’ Kesimpta can be self-administered, it will not be market leader currently, says GlobalData

Following the news that the European Medicines Agency (EMA) has approved Novartis’ Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults; Philippa Salter, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Kesimpta will provide a point of difference for MS patients as the first B-cell […]
Read more
1 … 67 68 69 70 71 … 110